Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.
about
Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune ResponseCD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells.Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsFavorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumorsAdoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escapeDefinitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral ImmunotherapyEnrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.Generation of CD8(+) T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy.DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
P2860
Q26744527-5094CBC4-ADD3-4CF4-A542-EB4430DC7B3AQ33931006-146C9EF6-2104-4860-BA3E-86A136AE9031Q34292741-9294DF56-0AB1-4F21-91CD-2AA2B7A555DFQ34764685-10CF2127-4A5A-4FDB-B132-7008D51E832FQ35212733-7B2DDCED-F94C-463A-A08F-3C6B34645D03Q35534823-573E0D9B-6CF0-47EA-B2F6-7ECBB8E2BE7AQ35673240-1641F922-CCBB-4D4E-AD7E-E4C99EB472FFQ36321054-9334D80A-A11E-4292-A404-B159BF40E956Q36928875-2D9622E4-CB29-4104-AE44-88CBAC99761EQ37370230-316EE863-C1FA-42B5-9A39-822938C2CD2AQ37477557-C01506AD-EBB2-48F7-BA81-32361461217BQ37690444-C86B9CA8-95EB-4307-9ECC-A472DB8BBD5FQ38852674-7240D8DD-F694-4BEB-9B3C-7AC4F9E2C433Q39199726-A149A618-1D42-4800-BF15-4F7FE0644711Q39290133-A7F259D7-C9E4-468C-842B-98A546EB4779Q41279759-2B4B48CF-BF52-4B1E-8FEA-0FF656ECB45DQ41875584-6E280B63-646C-49A8-8C49-0F9F3B411DC0Q47259954-5E379073-9345-42CE-B7B3-BD0980FA78FCQ47443248-06BBAD89-C9CE-4D66-B73B-5E5A6B17470FQ47781149-1623ACF0-2BF2-49CE-BB40-1CDEFF503197Q52746279-E83A811D-9659-4963-8AE8-2951BC608293Q54378300-19187A13-E4AA-4A5B-9C84-1921233F500EQ55518179-627408CF-C001-46D1-A158-7A985F0E3622
P2860
Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Adoptive T cell therapy promot ...... altered tumor escape variants.
@en
Adoptive T cell therapy promot ...... altered tumor escape variants.
@nl
type
label
Adoptive T cell therapy promot ...... altered tumor escape variants.
@en
Adoptive T cell therapy promot ...... altered tumor escape variants.
@nl
prefLabel
Adoptive T cell therapy promot ...... altered tumor escape variants.
@en
Adoptive T cell therapy promot ...... altered tumor escape variants.
@nl
P2093
P2860
P356
P1476
Adoptive T cell therapy promot ...... altered tumor escape variants.
@en
P2093
Darlene L Knutson
Heather C Flynn Gilmer
Jill M Thompson
Karen M Kaluza
Richard G Vile
Timothy J Kottke
P2860
P304
P356
10.1002/IJC.26447
P577
2011-11-30T00:00:00Z